This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.
Cardinal Health to Highlight Cost-Control Approach in ASHP
by Zacks Equity Research
Cardinal Health (CAH) helps hospitals identify hidden savings, improve patient outcomes and drive supply chain efficiencies.
Quest Diagnostics to Buy Laboratory Services Unit in Midwest
by Zacks Equity Research
Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.
CVS Health (CVS) Gets Final Approval to Close Aetna Deal
by Zacks Equity Research
Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.
Medtronic (MDT) Positive on Mazor Purchase, Rising Costs Ail
by Zacks Equity Research
The pending acquisition of Mazor Robotics holds great potential as it is likely to solidify Medtronic's (MDT) position in robotic spine surgery.
Align Technology's New iTero Scanner Updates to Boost Uptake
by Zacks Equity Research
Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.
Here's Why Investors Should Hold Medidata (MDSO) Stock Now
by Zacks Equity Research
Solid prospects in the Rave Genomics platform are likely to provide Medidata (MDSO) a competitive edge in the MedTech space.
Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull
by Zacks Equity Research
Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.
PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects
by Zacks Equity Research
PerkinElmer's (PKI) Vanadis NIPT is a more cost effective and non-invasive screening system compared to traditional ones.
Here's Why You Should Invest in Merit Medical (MMSI) Now
by Zacks Equity Research
A strong outlook for 2018 and a solid global foothold make Merit Medical (MMSI) a promising investment pick.
Here's Why You Should Invest in Abiomed (ABMD) Right Now
by Zacks Equity Research
Abiomed (ABMD) continues to gain from its flagship Impella; a strong fiscal 2019 outlook encourages.
Here's Why You Should Invest in Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation. Through fiscal 2018, new products generated more than $300 million in revenues.
Medtronic's Deal With Nutrino Health to Boost Diabetes Arm
by Zacks Equity Research
Bringing Nutrino under Medtronic's (MDT) Diabetes Group will help the acquirer speed up its growth in the same business.
Medtronic Gets Health Canada License for Visualase System
by Zacks Equity Research
Medtronic (MDT) adopts initiatives to boost top-line contributions from the Brain Therapies arm.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Can Segmental Growth Boost Veeva Systems' (VEEV) Q3 Earnings?
by Zacks Equity Research
Veeva Systems (VEEV) likely to gain from solid segmental show in fiscal Q3; competition stiff.
Veeva Systems (VEEV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Veeva (VEEV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher (TMO) Rides on APAC Strength Despite Cost Woes
by Zacks Equity Research
Thermo Fisher (TMO) is registering a sturdy global footprint with strong growth seen in Asia-Pacific including China.
Has Veeva Systems (VEEV) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
Express Scripts & Petco Tie Up, Ease Access to Pet Medicines
by Zacks Equity Research
Express Scripts' (ESRX) Inside Rx Pets discount card is likely to make pet medicines affordable.
Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business
by Zacks Equity Research
Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $85.52, moving +0.9% from the previous trading session.
Medtronic Moves a Step Ahead With Mazor Robotics Buyout
by Zacks Equity Research
Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.
Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm
by Zacks Equity Research
Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.